Words of Wisdom

A novel delivery system of gemcitabine called TAR-200 led to promising responses in certain patients with non-muscle-invasive bladder cancer.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

PET scans were helpful in determining which patients with HER2-positive early breast cancer may be able to skip chemotherapy.

Good news in the cancer space is great, but we need to share more cancer stories about the good, bad and the ugly